Citigroup’s Silence Therapeutics SLN Stock Holding History

Citigroup’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.67K	Buy	1,835 +214	+13%	+$1.18K	﹤0.01%	5054
2025 Q4	$9.86K	Sell	1,621 -152	-9%	-$973	﹤0.01%	5057
2025 Q3	$9.2K	Sell	1,773 -1,701	-49%	-$9.45K	﹤0.01%	5048
2025 Q2	$20.1K	Sell	3,474 -57,597	-94%	-$247K	﹤0.01%	5078
2025 Q1	$172K	Buy	61,071 +569	+0.9%	+$2.78K	﹤0.01%	4282
2024 Q4	$416K	Buy	60,502 +2,169	+4%	+$28K	﹤0.01%	3960
2024 Q3	$1.06M	Hold	58,333	–	–	﹤0.01%	3220
2024 Q2	$1.11M	Hold	58,333	–	–	﹤0.01%	2839
2024 Q1	$1.26M	Hold	58,333	–	–	﹤0.01%	2841
2023 Q4	$1.01M	Hold	58,333	–	–	﹤0.01%	2810
2023 Q3	$573K	Hold	58,333	–	–	﹤0.01%	2959
2023 Q2	$321K	Hold	58,333	–	–	﹤0.01%	3647
2023 Q1	$362K	Hold	58,333	–	–	﹤0.01%	3358
2022 Q4	$890K	Hold	58,333	–	–	﹤0.01%	2711
2022 Q3	$576K	Hold	58,333	–	–	﹤0.01%	3135
2022 Q2	$691K	Hold	58,333	–	–	﹤0.01%	2978
2022 Q1	$1.11M	Hold	58,333	–	–	﹤0.01%	2869
2021 Q4	$1.36M	Buy	+58,333	New	+$1.35M	﹤0.01%	2943

Other funds holding SLN

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Citigroup's SLN Position: Q1 2026 in Review

Citigroup increased its Silence Therapeutics (SLN) stake by 13% in Q1 2026, buying an estimated $1.18K and bringing the position to 1,835 shares worth $9.67K. The position accounts for ﹤0.01% of the portfolio, ranked #5054.

Citigroup first reported a position in SLN in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.36M in Q4 2021. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

Citigroup held 1,835 shares of Silence Therapeutics worth $9.67K as of Q1 2026.
Citigroup bought 214 Silence Therapeutics shares in Q1 2026, an estimated $1.18K.
Silence Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5054 holding.
Citigroup first reported a position in Silence Therapeutics in Q4 2021 and has held it in 18 quarters since.
Citigroup's Silence Therapeutics position peaked at $1.36M in Q4 2021.
56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.